CPT 81471: XLID Duplication and Deletion Gene Panel
Commercial payers pay $870 on average nationally for this procedure.
CPT code 81471 describes a laboratory genetic testing panel that evaluates a patient specimen for duplication and deletion mutations across at least 60 genes, including 15 genes associated with X-linked intellectual disability (XLID); this is a molecular diagnostic service typically performed by a clinical molecular genetics or cytogenetics laboratory and usually provided as a laboratory-based service in a clinical laboratory or reference lab setting.
Customize your policy alerts
Sign up for cpt 81471 policy alerts
Get alerted when payer policies referencing 81471 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial rates for CPT 81471 center around the BUCA average commercial rate of $870.40, with notable variation by insurer. Blue Cross Blue Shield presents a high mean and elevated 75th-percentile level suggesting upper-end pricing, while Cigna and UnitedHealth Group sit near the BUCA mean but with different skew: Cigna’s median and mean are closer together, whereas UnitedHealth Group’s median is lower than its mean. Aetna has a low mean and a very limited 90th-percentile presence relative to others, indicating less activity at higher price points.
Dispersion measured as P75–P25 highlights where rates are tight or wide: Blue Cross Blue Shield has a tight interquartile spread of $230.30 ($1,066.90–$834.60) versus Cigna’s wider spread of $738.90 ($1,207.90–$470.20). UnitedHealth Group shows moderate dispersion of $575.10 ($914.00–$383.90). BUCA’s interquartile spread is $323.80 ($912.80–$599.00). Aetna’s available percentiles are concentrated at lower values with P90 at $315.80, indicating limited upper-range variability.